Loading
Biohaven Ltd. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 09 Mar 2026.
Biohaven Ltd.: what insiders have been doing
Every trade that managers of Biohaven Ltd. disclose to SEC (Form 4) is tracked on this page. The company sits in the Healthcare & Pharma sector. In the past year (18 October 2025 to 18 October 2026), 11 filings came from 8 insiders.
The flow runs one way only: 4 insiders bought (5 purchases totalling €27.3M) and nobody sold on the market. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Biggest ticket of the year: €21.6M, bought by Childs John W and made public on 17 November 2025. On the buying side, the filings list 2 senior executives, 1 finance chief and 1 chief executive among the declarants.
With 11 filings in twelve months, the company is quieter than the median of 19 filings across the 5,811 companies we follow on the same exchange. Since 2022, the database holds 38 purchases and no sales by insiders of the company. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported net income of -738.8 m USD.
In all, 4 purchases were made within 30 days of a purchase by another insider of the company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. The latest purchase dates back some time: it was published 223 days ago, on 9 March 2026. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4.
In the same sector, recent insider purchases at Cooper Companies, Inc. and Anixa Biosciences Inc also feature in our signals. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
72
Thresholds
n/a
Buy Volume
€153M
38 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleJohn W. Childs4 buys
George C. Clark1 buy
Gregory Bailey1 buy
Vlad Coric1 buy
Since the insiders bought
- +21.4%Entry US$9.46 · Close at T+90 US$11.48
- +21.5%Entry US$9.45 · Close at T+90 US$11.48
- +21.5%Entry US$9.45 · Close at T+90 US$11.48
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Biohaven Ltd. Buy (bullish), based on 15 analysts. Average price target: US$21.27.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$11.42
Analyst consensus
15 analystsBuy
US$10.00Target US$21.27(+86%)US$42.00
Income statement
EBITDA-US$735.5M
Net income-US$738.8M0.0% margin
Valuation
PER (forward)-6.1x
P/Book141.0x
Beta3.20
Balance sheet & cash
Market capUS$1.7B
Total debtUS$284.6M
Free Cash Flow-US$610.2M
Debt / Equity2430%
Profitability & ownership
ROE-799.5%
ROA-72.0%
% insiders11.2%
% institutions95.7%
Last declaration on 19 March 2026
Declarations72 total
17,342 shares0Common SharesSEC:0001850520-26-000003:0
28,400 shares@ US$30.42660.055% mcap50.0% of flowCommon SharesSEC:0001027035-26-000006:0
Canonical exit: 2 Jun 2025 (T+90)
3,750 shares0Common SharesSEC:0001704186-26-000002:0
4,250 shares0Common SharesSEC:0001898799-26-000002:0
2,500 shares0Common SharesSEC:0001878290-26-000002:0
14,250 shares0Common SharesSEC:0001704317-26-000002:0
17,000 shares@ US$8.5159100.0% of flowCommon SharesSEC:0001878290-25-000004:0
Canonical exit: 15 Feb 2026 (T+90)
400,000 shares@ US$7.5030.2% of flowCommon SharesSEC:0001935979-25-000096:0
Canonical exit: 11 Feb 2026 (T+90)
333,333 shares@ US$7.507.7% of flowCommon SharesSEC:0001704317-25-000004:0
Canonical exit: 11 Feb 2026 (T+90)
3,333,333 shares@ US$7.5019.1% of flowCommon SharesSEC:0001027035-25-000004:0
Canonical exit: 11 Feb 2026 (T+90)
25,000 shares@ US$30.38590.6% of flowCommon SharesSEC:0001935979-25-000018:0
Canonical exit: 2 Jun 2025 (T+90)
14,250 shares0Common SharesSEC:0001935979-25-000002:0
2,500 shares0Common SharesSEC:0001935979-25-000004:0
4,250 shares0Common SharesSEC:0001935979-25-000003:0
3,750 shares0Common SharesSEC:0001935979-25-000005:0
29,000 shares@ US$35.94460.9% of flowCommon SharesSEC:0001935979-24-000088:0
Canonical exit: 30 Mar 2025 (T+90)
21,052 shares@ US$47.503.2% of flowCommon SharesSEC:0001935979-24-000077:0
Canonical exit: 31 Dec 2024 (T+90)
21,052 shares@ US$47.500.8% of flowCommon SharesSEC:0001935979-24-000078:0
Canonical exit: 31 Dec 2024 (T+90)
5,000 shares@ US$44.19322.3% of flowCommon SharesSEC:0001935979-24-000075:0
Canonical exit: 23 Dec 2024 (T+90)
28,400 shares@ US$35.66840.8% of flowCommon SharesSEC:0001562180-24-005805:0
Canonical exit: 16 Oct 2024 (T+90)
28,000 shares@ US$35.580.8% of flowCommon SharesSEC:0001562180-24-004529:0
Canonical exit: 28 Aug 2024 (T+90)
15,000 shares@ US$34.19185.5% of flowCommon SharesSEC:0001562180-24-004045:0
Canonical exit: 11 Aug 2024 (T+90)
25 of 72 declarations
About Biohaven Ltd.
Biohaven Ltd. (NYSE: BHVN) is a U.S.-listed biopharmaceutical company headquartered in New Haven, Connecticut, in the United States. The company’s current identity was shaped by a spin-off completed in 2022, following a long development history that includes licensing activity originating from Yale University and the build-out of proprietary drug-discovery platforms. Biohaven trades on the New York Stock Exchange under the BHVN ticker, making it a U.S. public-market name with a strong clinical-stage biotech profile. ([ir.biohaven.com](https://ir.biohaven.com/static-files/e1fdf95d-7215-455d-aaac-214c061b45fd))
Biohaven describes itself as a biopharmaceutical company focused on the discovery, development and commercialization of life-changing treatments across three core therapeutic areas: neuroscience, immunology and oncology. Its business model is centered on a pipeline of innovative assets rather than a large established commercial franchise, which means valuation is driven primarily by clinical progress, regulatory milestones and eventual commercialization outcomes. The company emphasizes proprietary science and drug-development platforms, aiming to address both rare diseases and larger indications with substantial unmet medical need. ([biohaven.com](https://www.biohaven.com/))
Read moreShow less
Among the company’s most important assets are Nurtec ODT (rimegepant) and Zavzpret (zavegepant), which helped establish Biohaven’s credibility in migraine and broader neuro-related drug development. Biohaven’s pipeline also includes troriluzole, a lead program in spinocerebellar ataxia (SCA), where the company has been pursuing regulatory approval, and BHV-8000, a brain-penetrant, orally administered TYK2/JAK1 inhibitor currently in a Phase 2/3 study in early Parkinson’s disease. In immunology, BHV-1300 has generated data showing sustained IgG lowering and is being positioned as a potential first-in-class degrader platform. These programs give the company several shots on goal, but they also keep Biohaven exposed to the binary nature of biotech execution risk. ([ir.biohaven.com](https://ir.biohaven.com/node/11101/pdf))
From a competitive standpoint, Biohaven is best viewed as a science-driven specialty biotech rather than a diversified pharmaceutical major. Its differentiation lies in its ability to advance novel mechanisms and move candidates through late-stage development with a focus on neurologic and immunologic diseases. Geographically, the company remains centered in the United States, with its headquarters in New Haven and additional operating footprints that support research and development activities, including sites in the U.S. and Ireland. ([ir.biohaven.com](https://ir.biohaven.com/static-files/625aec92-2813-4aeb-bb2d-9bfc3fc5317a?utm_source=openai))
Recent headlines have been important for the investment case. In February 2025, the FDA accepted Biohaven’s NDA for troriluzole and granted Priority Review, a meaningful regulatory step for a rare-disease program. In May 2025, Biohaven initiated a global Phase 2/3 study of BHV-8000 in early Parkinson’s disease. The company also announced a non-dilutive financing agreement with Oberland Capital for up to $600 million, strengthening its balance sheet and potentially funding later-stage development and strategic flexibility. For investors, Biohaven remains a high-risk, catalyst-driven U.S. biotech story listed on the NYSE, with upside tied to clinical and regulatory execution. ([ir.biohaven.com](https://ir.biohaven.com/node/11101/pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
